TFFP

TFF Pharmaceuticals, Inc. Common Stock

TFFP

Market cap $289K

Overview Fund Activity

Delisted

TFFP was delisted on the 12th of December, 2024.

Back to rankings

About: TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

Employees: 19

Healthcare Drug Manufacturers - General

Financial journalist opinion

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market.

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

TFF Pharmaceuticals Announces It Will Wind Down Operations

FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.

TFF Pharmaceuticals Announces It Will Wind Down Operations

Zacks Investment Research

TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why

TFF Pharmaceuticals (TFFP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution conditions FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announces its new partnership with Emory University and the Biomedical Advanced Research and Development Authority (BARDA).

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

Zacks Investment Research

TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates

TFF Pharmaceuticals, Inc. (TFFP) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $3.50 per share a year ago.

TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels -- leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC No production of donor-specific antibodies (DSA) after treatment with TFF TAC FORT WORTH, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection. “The growing body of data from the TFF TAC Phase 2 study continues to suggest that TFF TAC has transformative potential to advance the field of immunosuppressive therapy to prevent lung transplant rejection,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, “the trend is your friend, until it bends.

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

The Leidos team's Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company's Proprietary Thin Film Freezing Technology

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

See News Rankings

Charts implemented using Lightweight Charts™